(2026). Durability of the BNT162b2 XBB: 1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform. PLOS ONE.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Durability of the BNT162b2 XBB: 1.5-adapted Vaccine Against JN.1 Hospitalisation in Europe, October 2023 to August 2024: A Test-negative Case-control Study Using the Id.DRIVE Platform."
PLOS ONE 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Durability of the BNT162b2 XBB: 1.5-adapted Vaccine Against JN.1 Hospitalisation in Europe, October 2023 to August 2024: A Test-negative Case-control Study Using the Id.DRIVE Platform."
PLOS ONE, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.